Komori
J Frontier (2934) · TargetHigher Operating and Ordinary Profit, but Net Loss Attributable to ParentLatest Results briefing materials (2026-10-15): "Advanced"

Building a Stable Earnings Base

First written in FY2021. 10 of 23 entries say "Advanced", first in FY2022-Q1. Latest entry: 2026-10-15.

23entries
6years
9from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023-Q1 – FY2023-Q3RestatedFY2024-Q1 – FY2024-Q3AdvancedFY2025-H1 – FY20252021: 220212022: 420222023: 320232024: 120242025: 220252026: 112026
Same theme, other companies
Stabilizing the Revenue BaseA theme 95 companies write about · 0 as a headwind · 96 as a tailwind

22 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 95 companies compared. The sentences above are computed from all 95.
Full recordFilings, disclosures and news, newest first
  1. FY2026Higher Operating and Ordinary Profit, but Net Loss Attributable to ParentAnnual report

    「Revenue was 22,235,985 thousand yen, up 3.4% year on year; EBITDA was 964,376 thousand yen, up 7.1%; operating profit was 312,270 thousand yen, up 6.3%; ordinary profit was 415,178 thousand yen, up 79.3%; and the loss attributable to owners of parent was 321,314 thousand yen, compared with profit attributable to owners of parent of 87,570 thousand yen in the previous fiscal year.」

    Revenue, EBITDA, operating profit and ordinary profit increased, while profit attributable to owners of parent turned into a loss due to extraordinary losses and other factors.
  2. FY2026-H1WorsenedAnnual report

    「Revenue for the six months ended under review was ¥10,675,438 thousand, down 1.6% year on year; EBITDA (note) was ¥164,154 thousand, down 50.1%; operating loss was ¥142,778 thousand, compared with operating profit of ¥27,073 thousand in the previous year; ordinary loss was ¥131,763 thousand, compared with ordinary profit of ¥7,163 thousand; and interim net loss attributable to owners of the parent was ¥191,401 thousand, compared with an interim net loss attributable to owners of the parent of ¥21,455 thousand.」

    For the interim period, revenue and EBITDA were below the previous year, operating profit and ordinary profit turned into losses, and the interim loss attributable to owners of the parent widened.
  3. FY2025AdvancedAnnual report

    「As a result, revenue was ¥21,504,496 thousand, up 21.4% year on year; EBITDA (note) was ¥900,515 thousand, compared with negative ¥145,236 thousand in the previous year; operating profit was ¥293,746 thousand, compared with an operating loss of ¥605,179 thousand; ordinary profit was ¥231,541 thousand, compared with an ordinary loss of ¥694,719 thousand; and net income attributable to owners of the parent was ¥87,570 thousand, compared with a net loss attributable to owners of the parent of ¥2,101,074 thousand in the previous year.」

    Revenue increased, while EBITDA, operating profit, ordinary profit and net income attributable to owners of the parent all improved from losses in the previous year and turned profitable for the full year.
  4. FY2025-H1AdvancedAnnual report

    「We worked to strengthen our stable earnings base by expanding sales of “SOKUYAKU Benefit,” a corporate employee-benefits service launched in April 2024 to promote corporate health management.」

    The Company is working to strengthen its stable earnings base by expanding sales of SOKUYAKU Benefit.
  5. FY2024-Q3RestatedAnnual report

    「Marketing support services, including medical staffing placement and customer acquisition support, as well as other business-to-business services provided to affiliated medical institutions and pharmacies, continued to grow steadily. We are working to strengthen our revenue model by leveraging the foundation of the “SOKUYAKU” platform.」

    The Company continues to strengthen its revenue model through medical staffing placement, customer acquisition support and marketing support using the SOKUYAKU platform.
  6. FY2024-Q1RestatedAnnual report

    「Marketing support services, including medical staffing placement and customer acquisition support, as well as other business-to-business services provided to affiliated medical institutions and pharmacies, continued to grow steadily. We are working to strengthen our revenue model by leveraging the foundation of the “SOKUYAKU” platform.」

    The Company continues to strengthen its revenue model through medical staffing placement, customer acquisition support and marketing support using the SOKUYAKU platform.
  7. FY2023AdvancedAnnual report

    「The number of new subscription customers acquired during the year in the pharmaceutical mail-order businesses of the healthcare sales and medical care sales segments was 416,848, up 16.8% year on year, representing a significant increase in new subscription members as a result of effective advertising investment.」

    The number of new subscription customers for the year was 416,848, up 16.8% year on year.
  8. FY2023-Q3RestatedAnnual report

    「Marketing support services, including medical staffing placement and customer acquisition support, and contracted services for online medical consultation desks for local governments, as well as other business-to-business services provided to medical institutions, pharmacies, companies and local governments, continued to grow steadily. We are working to strengthen our revenue model by leveraging the foundation of the “SOKUYAKU” platform.」

    The Company continues to strengthen its revenue model through medical staffing placement, customer acquisition and marketing support, and online medical consultation desks for local governments.
  9. FY2023-Q1RestatedAnnual report

    「Marketing support services, including medical staffing placement and customer acquisition support, as well as other business-to-business services provided to affiliated medical institutions and pharmacies, continued to grow steadily. We are working to strengthen our revenue model by leveraging the foundation of the “SOKUYAKU” platform.」

    The Company continues to strengthen its revenue sources through medical staffing placement, customer acquisition support and marketing support using the SOKUYAKU platform.
  10. FY2022AdvancedAnnual report

    「The number of new subscription customers acquired during the year through the mail-order pharmaceutical businesses of the healthcare sales and medical care sales segments was 356,909, up 18.5% year on year, reflecting a substantial increase in new subscription-member acquisitions through effective advertising investment.」

    The company disclosed 356,909 new subscription customers for the year, an 18.5% year-on-year increase.
  11. FY2022-Q3RestatedAnnual report

    「We also promoted the diversification of our revenue sources, including the corporate online medical consultation service “SOKUYAKU ASP,” the “Tsuidegai Service” for drugstores and other businesses, and our medical staffing placement business.」

    The Company continues to diversify its revenue sources through SOKUYAKU-related services and medical staffing.
  12. FY2022-Q2AdvancedAnnual report

    「To respond to growing consumer awareness and demand regarding “未病,” we developed new advertising channels, including video advertising and social networking services, in addition to conventional web and television-based offline advertising, and actively invested in advertising, thereby acquiring a significant number of new subscription customers (61% progress toward the annual target for new subscription customers).」

    New subscription-customer acquisition reached 61% of the annual target through video and social-media advertising initiatives.
  13. FY2022-Q1AdvancedAnnual report

    「We have taken steps to build a stable earnings base and expand sales, including the launch of sales of two new in-house brands, “Kousuiso 328 Selection Mogitate Nama Smoothie Green” and “CaFelice (Cafe Liche).”」

    The company began selling 2 new products to build a stable earnings base.
  14. FY2021First statedAnnual report

    「Through the launch of new products and the expansion of services for subscription members, we will continue building a stable earnings base in the healthcare sales business, which sells health foods and other products by mail order, and the medical care sales business, which sells pharmaceuticals by mail order.」

    The company aims to secure stable earnings through new product launches and expanded services for subscription members.
Moved together

"SOKUYAKU Member and Partner Acquisition Results" moved the same way as this thread, in the same document, in 9 of its 23 moves.

987554★123456
  1. ★This thread
  2. 1SOKUYAKU Member and Partner Acquisition Results9×
  3. 2Expanding the SOKUYAKU platform8×
  4. 3Research and Development of New Products and Services7×
  5. 4Improving advertising efficiency and managing CPO5×
  6. 5Promoting M&A and alliances over the medium to long term5×
  7. 6Diversification of revenue streams through SOKUYAKU ASP, add-on purchases and healthcare staffing services4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for J Frontier yet. It last moved in the Results briefing materials of 2026-10-15: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Building a Stable Earnings Base | J Frontier Co.,Ltd. (2934) | Komori